Sygnis
SYGNIS is a German stocklisted company devoted to the development of novel, superior tools for molecular biology that play key roles in changing the way genomic and proteomic research is done today. SYGNIS specializes in the development and commercialization of proprietary technologies and a commercial product portfolio addressing key challenges in molecular biology. With the acquisition of Expedeon Holdings, Ltd. based in Cambridge, UK, SYGNIS has added a complementary proteomic product portfolio. With this significant expansion SYGNIS portfolio now covers the entire workflow of molecular biology. Products are sold through a direct sales force and distribution partners in Europe, the US and Asia. SYGNIS has offices in Germany, Spain and the UK, production sites in the UK and the US and sales offices in Asia. The company is listed on the German Stock Exchange in the Prime Standard segment (Ticker: LIO1; ISIN:
7-day free trial · no credit card
Verified contacts
2
available on Kipplo
LinkedIn employees
9
11 to 50 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 2 verified contacts at Sygnis
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
2 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Top roles at Sygnis
2 distinct titles indexed · top 2 shown.
- 1technical assistent
- 1técnico superior de laboratorio
Sign up to unlock all 2 contacts at Sygnis
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 2 verified contacts at Sygnis
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.